Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Managing diffuse large B-cell lymphoma

Christian Gisselbrecht • 5 Dec 2014
ASH 2014
B-Cell Lymphoma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses the molecular approach in managing diffuse large B-cell lymphoma (DLBCL). The molecularly defined DLBCL subtypes, germinal centre B-cell-like (GCB)-DLBCL and activated B-cell-like (ABC)-DLBCL, have important clinical implications.

More from Christian Gisselbrecht

2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
2:11
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
Christian Gisselbrecht • 31 Aug 2020

Related Videos

1:13
Antibody-drug conjugates for the treatment of lymphoma
Pau Abrisqueta • 5 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:06
Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals